Sathya Ganesan, Chang Ching-yi, Kazmin Dmitri, Cook C Edgar, McDonnell Donald P
Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA.
Cancer Res. 2003 Nov 15;63(22):8029-36.
The androgen receptor (AR), a member of the nuclear receptor family, is a ligand-inducible transcription factor. In the prostate gland, androgens regulate the transcription of several genes that ultimately result in cell growth and differentiation. With a goal of developing tissue-selective AR modulators that can be used to treat prostate cancer and other androgenopathies, we have taken an approach to identify androgens that function in a manner distinct from the physiological androgens testosterone and dihydrotestosterone. Classical AR agonists function by binding to and inducing a conformational change in the receptor. This facilitates the obligate interaction of the amino and carboxyl terminus of the receptor, recruitment of coactivators, and subsequent regulation of target genes. On the basis of this paradigm, we screened a library of potential AR agonists for compounds that induce an "activating" conformational change in the receptor structure but that do not facilitate a high-affinity intermolecular interaction between the amino and carboxyl terminus. Compounds identified in this manner behaved as partial agonists of AR-mediated transcription in a variety of assays. Additional compounds were identified in this screen that did not allow the activation function-2 coactivator pocket to form and were demonstrated to function as weak agonists of AR-mediated transcription. Surprisingly, when we examined the ability of these compounds to induce cell proliferation, we observed that despite having different degrees of partial agonist activities on classical transcriptional responses (i.e., induction of prostate-specific antigen), these compounds were as efficacious as dihydrotestosterone in stimulating proliferation. The unexpected finding that AR-mediated transcription and proliferation can be uncoupled suggests that AR is not used in the same manner in all androgen-regulated biological processes.
雄激素受体(AR)是核受体家族的成员,是一种配体诱导型转录因子。在前列腺中,雄激素调节多个基因的转录,最终导致细胞生长和分化。为了开发可用于治疗前列腺癌和其他雄激素疾病的组织选择性AR调节剂,我们采用了一种方法来鉴定功能与生理性雄激素睾酮和双氢睾酮不同的雄激素。经典的AR激动剂通过与受体结合并诱导其构象变化来发挥作用。这促进了受体氨基末端和羧基末端的必然相互作用、共激活因子的募集以及随后对靶基因的调控。基于这一模式,我们针对能在受体结构中诱导“激活”构象变化但不促进氨基末端和羧基末端之间高亲和力分子间相互作用的化合物,筛选了一个潜在AR激动剂文库。以这种方式鉴定出的化合物在各种测定中表现为AR介导转录的部分激动剂。在该筛选中还鉴定出了其他化合物,它们不允许激活功能-2共激活因子口袋形成,并被证明作为AR介导转录的弱激动剂发挥作用。令人惊讶的是,当我们检测这些化合物诱导细胞增殖的能力时,我们观察到尽管它们对经典转录反应(即前列腺特异性抗原的诱导)具有不同程度的部分激动剂活性,但这些化合物在刺激增殖方面与双氢睾酮一样有效。AR介导的转录和增殖可以解偶联这一意外发现表明,AR在所有雄激素调节的生物学过程中的使用方式并不相同。